Myocardial Viability (FDG PET)¹⁸F-FDG + perfusion tracer
Perfusion/metabolism imaging to identify hibernating, salvageable myocardium
Quick Answer
Viability imaging identifies dysfunctional but living (hibernating) myocardium that could recover function after revascularization. The reference test pairs a perfusion study with FDG metabolism: a perfusion–metabolism mismatch (reduced perfusion but preserved/increased FDG uptake) indicates viable myocardium; a match (both reduced) indicates scar. Preparation is the mirror image of cardiac-sarcoid imaging — here you promote myocardial glucose uptake.
Definition
Myocardial viability refers to dysfunctional myocardium that is alive and potentially recoverable rather than irreversibly infarcted. The clinical question is whether regional/global left-ventricular dysfunction in ischemic cardiomyopathy will improve after revascularization.
Pathophysiology
- Hibernating myocardium: chronically hypoperfused tissue that downregulates contraction to survive, retaining membrane integrity and metabolism; it can recover contractile function if blood flow is restored.
- Stunned myocardium: transient dysfunction after an ischemic insult with normal or restored perfusion, recovering over time without revascularization; repetitive stunning overlaps with hibernation.
- Scar: infarcted, non-viable tissue — no metabolic activity and no recovery potential.
Clinical Importance
In ischemic cardiomyopathy with LV dysfunction, distinguishing hibernating myocardium from scar informs whether revascularization is likely to improve function and outcomes — a decision carrying real procedural morbidity and cost. Viability imaging is one input into a multidisciplinary revascularization decision.
The Concept — Perfusion vs Metabolism
Viable but hibernating myocardium shifts to glucose as its preferred substrate, so it takes up FDG despite reduced perfusion — the signature mismatch. Scar takes up neither. This pairing (a perfusion tracer + FDG) is the PET reference standard for viability.
Preparation (Mirror Image of Sarcoid Imaging)
Unlike cardiac-sarcoid imaging (which suppresses physiologic myocardial glucose uptake), viability imaging enhances it: a glucose load ± insulin — or a formal glucose–insulin clamp — drives FDG into viable myocardium so it is well visualized. Good glycemic management is essential, especially in diabetics, where poor glucose control is the commonest cause of a non-diagnostic study.
Protocol
Rest perfusion imaging (a PET perfusion tracer, or SPECT perfusion) + FDG-PET metabolism, compared segment by segment across the 17-segment model.
Interpretation
| Perfusion | FDG uptake | Meaning |
|---|---|---|
| Reduced | Preserved/increased (mismatch) | Viable — hibernating myocardium |
| Reduced | Reduced (match) | Non-viable — scar |
| Normal | Normal | Normal myocardium |
The greater the extent of mismatch, the greater the potential functional benefit from revascularization.
Imaging Modalities for Viability
| Method | Viability signal | Notes |
|---|---|---|
| FDG-PET + perfusion | Perfusion–metabolism mismatch | Reference standard; needs glucose prep |
| Thallium-201 SPECT | Redistribution/reinjection fill-in | Delayed/reinjection imaging; classic |
| Tc-99m gated SPECT | Preserved wall thickening/uptake | Thickening in a fixed defect suggests viability |
| Dobutamine stress echo | Contractile reserve (biphasic response) | Functional, no radiation |
| Cardiac MRI (LGE) | Transmural extent of scar | < 50% transmural LGE predicts recovery |
Evidence Nuance
Observational data (Allman meta-analysis) linked viability to improved survival after revascularization. However, the randomized STICH viability substudy found that viability identified higher-survival patients yet did not independently predict the benefit of CABG over medical therapy — so viability informs, rather than dictates, the revascularization decision, which integrates symptoms, anatomy, ischemia, and surgical risk.
Reporting Checklist
- Confirm glucose preparation adequacy and image quality.
- Report segment-by-segment perfusion–metabolism concordance: extent of mismatch (viable) vs match (scar).
- Quantify extent of viable/hibernating myocardium (segments / % LV) relevant to revascularization benefit.
- Integrate with LV function; state that viability informs (not dictates) the revascularization decision.
Common Pitfalls
- Poor glucose control → non-diagnostic FDG images (the most common failure).
- Reading FDG without the paired perfusion dataset — mismatch cannot be assessed.
- Overstating that mismatch mandates revascularization (STICH nuance).
- Attenuation/technical artifacts mimicking matched defects.
Board Pearls
Reduced perfusion + preserved/increased FDG = mismatch = viable (hibernating) myocardium; reduced perfusion + reduced FDG = match = scar. The larger the mismatch, the greater the potential functional benefit from revascularization.
Preparation is the mirror image of cardiac-sarcoid imaging: here you promote myocardial FDG uptake with a glucose load ± insulin (or glucose–insulin clamp). Poor glycemic control is the commonest cause of a non-diagnostic viability study.
Viability informs but does not dictate revascularization: the STICH substudy showed viability marked higher-survival patients yet did not independently predict CABG benefit over medical therapy. Alternative viability methods — thallium redistribution/reinjection, Tc-99m gated wall-thickening, dobutamine-echo contractile reserve, and CMR late-gadolinium transmurality (< 50% predicts recovery) — each read viability through a different lens.
Related Pages
- Protocol: Cardiac PET perfusion and MPI interpretation & grading.
- Contrast: Cardiac sarcoidosis (suppression protocol — the opposite preparation).
- Tracer: FDG; thallium-201 (redistribution viability).
Figure / Diagram Suggestions
- A mismatch vs match polar-map teaching pair (viable vs scar).
- A preparation contrast graphic: viability (promote FDG) vs sarcoid (suppress FDG).
- A modality comparison panel (PET mismatch, thallium reinjection, CMR LGE transmurality).
Self-Check (Board-Style)
Q1. A segment shows reduced perfusion but preserved FDG uptake. Viable or scar?
Answer: Viable — this perfusion–metabolism mismatch indicates hibernating myocardium that may recover after revascularization.
Q2. How does patient preparation for viability imaging differ from cardiac-sarcoid FDG imaging?
Answer: Viability imaging promotes myocardial glucose uptake (glucose load ± insulin / clamp) so viable myocardium is seen; sarcoid imaging suppresses it (high-fat/low-carb + fast ± heparin) so only inflammation lights up.
Q3. The FDG images are non-diagnostic with patchy, poor myocardial uptake in a diabetic. Most likely cause?
Answer: Poor glucose control — the commonest cause of a non-diagnostic viability study; adequate glycemic management (or a glucose–insulin clamp) is essential.
Q4. Does a large mismatch mandate revascularization?
Answer: No — the STICH substudy showed viability identifies higher-survival patients but did not independently predict CABG benefit over medical therapy. Viability informs a multidisciplinary decision.
Evidence & sources
https://nuc.med/myocardial-viability/ Report an issue